EP1425004A1 - Utilisation de composes en tant qu'antagonistes fonctionnels des recepteurs cannabinoides centraux - Google Patents

Utilisation de composes en tant qu'antagonistes fonctionnels des recepteurs cannabinoides centraux

Info

Publication number
EP1425004A1
EP1425004A1 EP02764671A EP02764671A EP1425004A1 EP 1425004 A1 EP1425004 A1 EP 1425004A1 EP 02764671 A EP02764671 A EP 02764671A EP 02764671 A EP02764671 A EP 02764671A EP 1425004 A1 EP1425004 A1 EP 1425004A1
Authority
EP
European Patent Office
Prior art keywords
fact
use according
chosen
disorders
residue
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP02764671A
Other languages
German (de)
English (en)
Inventor
Alberta Leon
Maurizio Dalle Carbonare
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
RESEARCH & INNOVATION S.P.A.
Original Assignee
Research & Innovation Soc Coop A Rl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Research & Innovation Soc Coop A Rl filed Critical Research & Innovation Soc Coop A Rl
Publication of EP1425004A1 publication Critical patent/EP1425004A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Definitions

  • the present invention is related to the use of acylamides as functional antagonists to the central cannabinoid receptors. STATE OF THE ART
  • Cannabis sativa in addition to being one of the most diffuse recreational drugs in the world, has been used for medical reasons for centuries for its multiple pharmacological effects, the use of which has, however, been limited in the last century mostly for its psychoactive effects on the CNS.
  • the principal active component identified is ⁇ 9 -tetrahydrocannabinol ( ⁇ 9 -THC) which, in fact, in addition to possessing psychotropic activity, produces an innumerable series of pharmacological effects both in humans and in animals demonstrating therefore great therapeutic potential, however limited by the central effects mentioned.
  • the so-called central receptor because it was initially identified in areas of the CNS and considered the molecular transducer of the central effects of cannabinoids and ii) the so-called peripheral receptor initially identified in peripheral tissues and in turn however considered the molecular transducer of the peripheral effects.
  • the central receptors are present in fact in high concentrations in the CNS, and more precisely in the cerebral cortex, hippocampus, caudate-putamen nuclei, substantia nigra, pars reticulata, globus pallidus, endopeduncular nucleus, cerebellum and spinal medulla.
  • central receptors are however also present at the peripheral level principally in correspondence with nerve endings as for example in the intestine, as well as on endothelium and on immunocompetent cells.
  • peripheral receptors have been principally identified at the peripheral level and above all in immunocompetent cells as for example T- lymphocytes, mastocytes, macrophages, etc.
  • the central receptors are considered to mediate not just the "undesired effects” of cannabinoids (such as the psychoactive effects, loss of memory and attention-span, loss of motor co-ordination etc.) but also some of their therapeutically “desired effects” (analgesic effect, anti-hyperalgic, appetite stimulation, ocular hypotension, etc.).
  • the peripheral receptors like the central receptors present in the immunocompetent cells, have been associated with the more peripheral effects of cannabinoids as for example the anti-inflammatory effect (Amen A. 1999 ref. cit).
  • cannabinomimetic molecules such as the classical cannabinoid agonists (e.g. ⁇ 8 -THC, ⁇ 6 -THC etc.) and non-classical cannabinoid and their derivatives (e.g. CP 55940, HU-210 etc.), derived from the endocannabinoids (e.g. metanandamide, etc.), aminoalkylindoles (e.g. Win 55-212) and molecules capable of interfering with the uptake and the inactivation of the endocannabinoids (e.g.
  • AM 404 trifluoromethylketones, etc.
  • synthetic derivatives have also been characterised, e.g. pyrrolic derivatives (e.g. SR141716, SR144528), with antagonistic activity towards cannabinoid receptors, believed to be useful in the control of eating disorders, in memory improvement and motor activity and for the weaning from dependency in tobacco as well as cannabis smokers (Ameri A. 1999 ref. cit).
  • PEA N- acylethanolamides
  • This family comprises derivatives of ethanolamine conjugated with acid radicals, both saturated (PEA) and unsaturated (ANA).
  • ANA and PEA can be produced and released by neuronal cells following excitation suggesting that these molecules may act as neurotransmitter belonging to the endocannabinoids system.
  • anandamide in vivo provokes cannabinoid-like effects, such as hypothermia, hypomotility, catalepsy, etc.
  • these effects have never been reported after administration of PEA in vivo, a result compatible with the absence of affinity of this molecule for the central receptor.
  • PEA and ANA are both able to exercise anti-inflammatory effects in vivo, there are disagreements regarding the capacity of PEA, in contrast to that of ANA, to interact with the peripheral cannabinoid receptors (Sugiura T. et al. 2000 J. Biol. Chem.
  • PEA is capable of significantly reducing the release of pro- inflammatory mediators from stimulated mastocytes in vitro, through an action on the peripheral receptors expressed on these cells (Facci L et al. 1995 ref. cit), more recent experiments conducted on transfected cell lines overexpressing the peripheral receptor have demonstrated that PEA is not able to displace the binding of cannabinoidmimetic molecules to this receptor (Sugiura T. et al. 2000 ref. cit).
  • PEA and analogues have been indicated as possessing neuroprotective activity in vitro and as such useful in pathological conditions associated with neuronal death (WO 9525509 and WO 9618600). This effect has been observed in vitro in newborn mouse cerebellum granule cells which express the peripheral receptor or a CB2-like receptor (Skaper S.D. et al. 1996 ref.cit). Furthermore, a patent application has recently been filed for the use of PEA as a cardio-protective (WO01/28588), an effect mediated also in this case likewise by peripheral receptors, because it is antagonised by SR 144528, antagonist of the peripheral receptor, and not by SR 141716, antagonist of the central receptor.
  • Ri — CO — can be an acyl residue of a saturated organic acid, linear or branched comprising from 10 to 20 C atoms — N — R 2 can be:
  • an aminohydroxyalkyl residue linear or branched comprising from 2 to 6 C atoms, optionally substituted with one or more aromatic groups on the alkyl chain
  • - an aminoacid residue of the series ⁇ , ⁇ or ⁇ R 3 can be H or CH 3 or where -N — R 2 ,R 3 form with the N atom a cyclic aminoether comprising from 5 to 7 C atoms, optionally substituted with linear or branched alkyl groups, behave as functional antagonists of the central cannabinoid receptors. They can therefore be usefully employed as drugs in pathological states or disorders which can be controlled through a reduction of the functionality of these receptors or through a reduction of the effect of the same endocannabinoids caused by a reduced availability or affinity of the receptors.
  • the subject of the present invention is the use of said saturated acylamides, or esters or salts of the same, for the preparation of pharmaceutical compositions for the treatment of pathological states or disorders connected with an altered functionality and/or "abusive" activation of the central cannabinoid receptors.
  • the aims and advantages of the therapeutic use of the saturated acylamides as functional antagonists of central cannabinoid receptors in pathological states or disorders which can be controlled by reducing the functionality of these receptors or impeding the activity of endocannabinoids, subject of the present invention, will be better understood in the course of the following detailed description.
  • the applicant has in fact found surprisingly that after repeated administration of saturated acid acylamides, a marked reduction in the receptor density of the central cannabinoid receptors at the level of the spinal medulla, and a reduction of the affinity constant (Kd), still for these receptors, in different cerebral areas (cerebellum, cortex, hippocampus) have been observed.
  • Ri — CO — can be an acyl residue of a saturated organic acid, linear or branched, comprising from 10 to 20 C atoms
  • R 2 can be: - an aminohydroxyalkyl residue, linear o branched, comprising from 2 to 6 C atoms, optionally substituted with one or more aromatic groups on the alkyl chain, and the hydroxyl group can be optionally esterified with a pharmaceutically suitable acid group, as for example acetic, tartaric and succinic or equivalent
  • R3 can be H or CH 3 or where -N — R 2 .R3 forms with an atom of N a cyclic aminoether comprising from 5 to 7 C atoms optionally substituted with linear or branched alkyl groups,
  • R 1 — CO — can be preferentially selected from the group constituted by aliphatic saturated monocarboxylic acids as for example decanoic acid, lauric, myristic, palmitic, stearic or arachidic acids and
  • N — R2 when present as an aminohydroxyalkyl residue, can be preferentially chosen, for example, from the group constituted by monoethanolamine, 2- hydroxypropylamine, whilst when it is the residue of an ⁇ , ⁇ o ⁇ aminoacid it can be chosen from the group constituted by serine, glycine, ⁇ -alanine, ⁇ -aminobutyric, phenylalanine and tyrosine instead when -N — R 2 ,R 3 form, with an atom of N, a cyclic aminoether, this is preferentially morpholine.
  • the saturated acylamides described in the present invention can be prepared according to various methods and preferably through fusion of the alkylamine salt with a carboxylic acid and formation of the corresponding alkylamide, or through acylation of the alkylamine nitrogen with appropriate activated carboxylic derivatives. Following are reported, for illustration, and not limiting purpose, some examples of saturated monocarboxylic acid amides.
  • Example 1 Preparation of N-(2-hydroxyethyl)-palmitoyl amide
  • the reaction mixture has then been crystallised from 95% ethanol.
  • the crystalline body has been then separated by filtration using a buchner, washed three times with cold 95% ethanol and then taken to dryness under vacuum.
  • the yield of the reaction has been approximately 85%.
  • Example 5 Preparation of N-palmitoyl-morpholinamide
  • morpholine 8.6 mmol
  • triethylamine 9 mmol
  • dimethylformamide 50 ml
  • To the solution have been added, dropwise, 2.35 g of palmitoyl chloride (8.5 mmol) dissolved in dimethylformamide, and made to react for 1 hour at 0°C and for 5 hours at room temperature.
  • the suspension obtained has been taken to dryness in a evaporator at reduced pressure.
  • the solid residue has then been washed with ethyl ether and crystallised from 70% ethanol.
  • the crystalline body was separated by filtration using a buchner, washed three times with cold 70% ethanol and then taken to dryness under vacuum.
  • the yield of the reaction has been approximately 85%.
  • Example 13 Preparation of N-palmitoyl- ⁇ -alanine 1.5 g of ⁇ -alanine (17 mmol) have been dissolved at 4°C in 1 M potassium hydroxide. To the solution have been added, dropwise and with continuous stirring, 2.75 g of palmitoyl chloride (10 mmol). The reaction mixture has been maintained at 0°C for 16 hours and, following this time, acidified with 6N HCI and extracted with ethyl acetate. The organic phase has been anhydrated with sodium sulphate and evaporated in a evaporator under reduced pressure. The residue was crystallised from (tert-butyl) methylether. The crystalline residue, separated by filtration using a buchner, has been washed three times with cold (tert-butyl) methylether and taken to dryness under vacuum.
  • the yield of the reaction has been approximately 80%.
  • the saturated fatty acid amide derivatives herein described have surprisingly been demonstrated to act, after repeated administration in normal adult rats, as functional antagonists of the central cannabinoid receptors, in that a reduction of the number of receptors or of their affinity, results in a reduction of their activity, without determining the cannabinomimetic effects known to be modulated by the central receptors (e.g. hypothermia, motor deficiency, etc.).
  • the derivatives described in the present invention decrease food intake both after acute or chronic administration.
  • the effects on the drastic reduction of the number of the central receptors at the level of the spinal medulla and the significant diminution of the affinity of this receptor in other areas of the CNS are described below in detail. Also described below is the behavioural/pharmacological effect on food intake and body weight after administration of compounds of the present invention.
  • the cannabinoid receptors have been characterised using receptor binding techniques. These analyses have been carried out on cells membrane preparations from different areas of the CNS from animals treated repeatedly with the compounds described herein and compared with animals treated with just carrier. a) Treatment of animals
  • Rats Male male Sprague Dawley rats have been used, weighing 200-300 g (Harlan- Italy, San Pietro al Natisone, UD, Italia). The animals, maintained on "normal" diets, have received two daily administrations (10mg/Kg peros) of the compounds herein described, for 10 days.
  • the nervous tissue membranes have been prepared by the removal and rapid freezing at -80°C of the following cerebral areas: spinal medulla, cortex, hippocampus and cerebellum.
  • the tissue have been weighed and suspended in 30 volumes of cold 50 mM Tris-HCI pH 7.4 buffer containing 0.25% of Soybean Type II Trypsin inhibitor, 1 mM EDTA and 4mM MgCb, and has been homogenised with 10 "strokes" in a Potter Teflon/glass homogeniser. After successive centrifugation and washing of the membranes, the pellet has been resuspended in a small volume (approx 1.5ml per g of starting tissue wet weight) of 50 mM Tris-HCI pH 7.4 buffer containing 1 mM EDTA, 4mM MgCI2 and 0.05% Fatty Acid Free BSA. Protein concentration has been determined on these samples by the bicinchinonic acid method.
  • the 3 H-WIN55,212-2 possessing a high affinity for the central cannabinoid receptors, has been used at a concentration of around 1-2 nM, whilst the final concentration of cold WIN55.212-2 used to obtain the total displacement of the label from its receptors was from 1 to 10 ⁇ M.
  • the final volume was 1ml, constituted by: 870 ⁇ l of binding buffer, 10 ⁇ l of DMSO, 10 ⁇ l of 3 H-WIN55,212-2 100nM, 10 ⁇ l of PMSF 1mM in 1% DMSO and 100 ⁇ l of synaptosomal membrane enriched preparation from nervous tissue (concentration of the homogenate around 1-2 ⁇ g of protein per ⁇ l).
  • mice (18-22 g) were housed single per cage under standard conditions. Drugs were dissolved in a vehicle consisting of cremophor/ethanol/saline (1:1 :18 by volume) or suspended in carboxymethylcellulse (CMC) 0.5% in PBS.
  • CMC carboxymethylcellulse
  • Results are presented as means + SEM and were analysed with an analysis of variance ANOVA followed by Student-Newman-Keuls' test with the level of significance set at P-0.05.
  • acylamides obtained following systemic administration in vivo described in the present invention, characterise these compounds as functional antagonists of the central cannabinoid receptors usefully employable therefore for the preparation of pharmaceutical compositions for the therapeutic treatment, alone or in association with other therapeutic agents selected for the specific pathological state or disorders, as for example drugs: anti-epileptics, neuroleptics, atypical neuroleptics, anti-depressives, dopaminergics, dopamine agonists, gaba agonists, weight control drugs, for memory improvement, anti-inflammatory/anti-pain (e.g..
  • opiods salicilates, pyrazoles, indoles, arylanthranyles, arylpropionates, arylacetates, oxicam, pyrano carboxylates, glucocorticoids), cathartics (emollients, osmotics, salines, irritants), of pathologic states or disorder connected with altered functionality and/or "abusive" activation of the central cannabinoid receptors and as such in:
  • the administration routes that can be used for the preventive or therapeutic treatment of the pathological states or disorders according to the present invention can be oral, parenteral, intramuscularly, subcutaneous or intravenously, and the topical administrations can be transdermical, including rectal, sublingual and intranasal.
  • the compounds, according to the therapeutic use as functional antagonists of the central cannabinoid receptors can be administered in pharmaceutical compositions in combination with excipients, dispersants and diluents compatible with the pharmaceutical uses known or new, with the aim of obtaining an improved delivery of the active ingredient to the site of action and to obtain a rapid effect, sustained or delayed in time. For this aim therefore fast, sustained or slow release pharmaceutical compositions can be used.
  • the dosages are dependent on the severity of the pathology or disorder and on the chosen route of administration, as well as on the state (age, body weight, general health condition) of the patient.
  • the dosage may range between 1 mg/Kg and 50 mg/Kg in daily repeated administrations for a period ranging from 2 to 16 weeks.
  • compositions in the form of dispersible granular powders, tablets, pills, hard and soft gelatine capsules, suspensions are suitable; for parenteral administration intramuscularly, subcutaneously, intravenously or peridurally, compositions in the form of buffered aqueous solutions, oil suspensions or lyophilised powders dispersible in appropriate solvents at the time of administration can be suitable; for topical administration transdermally, rectally, intranasally or sublingually, compositions in appropriate excipients or dispersants in the form of patches, suppositories, ovules, aerosols and sprays can be suitable.

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne l'utilisation de dérivés d'acylamides d'acides gras saturés en tant qu'antagonistes fonctionnels des récepteurs cannabinoïdes centraux. Ces molécules, dépourvues per se des effets psychotropes que présentent les cannabinoïdes, aminoalkylindoles, et endocannabinoïdes classiques connus à ce jour, peuvent se comporter comme des antagonistes fonctionnels des récepteurs cannabinoïdes centraux, lorsqu'elles sont administrées par des voies différentes. Pour leur activité pharmacologique, leur utilisation est ainsi appropriée en tant que médicaments dans des états ou des troubles pathologiques qui peuvent être maîtrisés par une réduction de la fonctionnalité desdits récepteurs ou par une réduction de l'effet des mêmes endocannabinoïdes également causée par une disponibilité ou un affinité réduite des récepteurs.
EP02764671A 2001-07-11 2002-07-11 Utilisation de composes en tant qu'antagonistes fonctionnels des recepteurs cannabinoides centraux Withdrawn EP1425004A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IT2001MI001483A ITMI20011483A1 (it) 2001-07-11 2001-07-11 Uso di composti come antagonisti funzionali ai recettori centrali deicannabinoidi
ITMI20011483 2001-07-11
PCT/EP2002/007722 WO2003006007A1 (fr) 2001-07-11 2002-07-11 Utilisation de composes en tant qu'antagonistes fonctionnels des recepteurs cannabinoides centraux

Publications (1)

Publication Number Publication Date
EP1425004A1 true EP1425004A1 (fr) 2004-06-09

Family

ID=11448045

Family Applications (1)

Application Number Title Priority Date Filing Date
EP02764671A Withdrawn EP1425004A1 (fr) 2001-07-11 2002-07-11 Utilisation de composes en tant qu'antagonistes fonctionnels des recepteurs cannabinoides centraux

Country Status (3)

Country Link
EP (1) EP1425004A1 (fr)
IT (1) ITMI20011483A1 (fr)
WO (1) WO2003006007A1 (fr)

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9910393D0 (en) 1999-05-05 1999-07-07 Lucas Ind Plc Electrical generator,an aero-engine including such a generator and an aircraft including such a generator
ATE486842T1 (de) 2002-03-12 2010-11-15 Merck Sharp & Dohme Substituierte amide
US7105526B2 (en) 2002-06-28 2006-09-12 Banyu Pharmaceuticals Co., Ltd. Benzimidazole derivatives
EP1546115A4 (fr) 2002-09-27 2010-08-04 Merck Sharp & Dohme Pyrimidines substituees
US7129239B2 (en) 2002-10-28 2006-10-31 Pfizer Inc. Purine compounds and uses thereof
US7247628B2 (en) 2002-12-12 2007-07-24 Pfizer, Inc. Cannabinoid receptor ligands and uses thereof
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
US7329658B2 (en) 2003-02-06 2008-02-12 Pfizer Inc Cannabinoid receptor ligands and uses thereof
ITMI20030210A1 (it) * 2003-02-07 2004-08-08 Res & Innovation Soc Coop A R L Composti endocannabinoido-simili e loro impiego
US7176210B2 (en) 2003-02-10 2007-02-13 Pfizer Inc. Cannabinoid receptor ligands and uses thereof
FR2851460B1 (fr) * 2003-02-21 2007-05-11 Seppic Sa Utilisation de n-lauroyl aminoacides comme actif cosmetique et pharmaceutique amincissant
US7141669B2 (en) 2003-04-23 2006-11-28 Pfizer Inc. Cannabiniod receptor ligands and uses thereof
US7145012B2 (en) 2003-04-23 2006-12-05 Pfizer Inc. Cannabinoid receptor ligands and uses thereof
US7268133B2 (en) 2003-04-23 2007-09-11 Pfizer, Inc. Patent Department Cannabinoid receptor ligands and uses thereof
US7232823B2 (en) 2003-06-09 2007-06-19 Pfizer, Inc. Cannabinoid receptor ligands and uses thereof
CN1902177A (zh) 2003-09-22 2007-01-24 万有制药株式会社 新哌啶衍生物
JP2007510647A (ja) 2003-10-30 2007-04-26 メルク　エンド　カムパニー　インコーポレーテッド カンナビノイド受容体調節剤としてのアラルキルアミン類
EP1718602A4 (fr) * 2004-01-30 2007-12-12 Peplin Biolipids Pty Ltd Molecules porteuses et therapeutiques
WO2005097127A2 (fr) 2004-04-02 2005-10-20 Merck & Co., Inc. Methode destinee a traiter des hommes presentant des troubles metaboliques et anthropometriques
BRPI0610580B8 (pt) 2005-05-30 2021-05-25 Banyu Pharma Co Ltd composto derivado de piperidina
AU2006277253A1 (en) 2005-08-10 2007-02-15 Msd K.K. Pyridone compound
AU2006282260A1 (en) 2005-08-24 2007-03-01 Msd K.K. Phenylpyridone derivative
JPWO2007029847A1 (ja) 2005-09-07 2009-03-19 萬有製薬株式会社 二環性芳香族置換ピリドン誘導体
WO2007049798A1 (fr) 2005-10-27 2007-05-03 Banyu Pharmaceutical Co., Ltd. Nouveau derive de benzoxathiine
NZ568292A (en) 2005-11-10 2011-08-26 Msd Kk Spiro[cyclohexane-1,1'-(3'H)-4'-azaisobenzofuran]-4-carboxamide derivatives
JPWO2008038692A1 (ja) 2006-09-28 2010-01-28 萬有製薬株式会社 ジアリールケチミン誘導体
AU2008233662B2 (en) 2007-04-02 2012-08-23 Msd K.K. Indoledione derivative
EA020466B1 (ru) 2007-06-04 2014-11-28 Синерджи Фармасьютикалз Инк. Агонисты гуанилатциклазы, пригодные для лечения желудочно-кишечных нарушений, воспаления, рака и других заболеваний
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
AU2009220605A1 (en) 2008-03-06 2009-09-11 Msd K.K. Alkylaminopyridine derivative
AU2009229860A1 (en) 2008-03-28 2009-10-01 Msd K.K. Diarylmethylamide derivative having antagonistic activity on melanin-concentrating hormone receptor
EP2274331B1 (fr) 2008-05-02 2013-11-06 Novartis AG Molécules de liaison à base de fibronectine améliorées et leurs utilisations
EP2810951B1 (fr) 2008-06-04 2017-03-15 Synergy Pharmaceuticals Inc. Agonistes de guanylate cyclase utile dans le traitement de troubles gastro-intestinaux, d'une inflammation, d'un cancer et d'autres troubles
US20110071129A1 (en) 2008-06-19 2011-03-24 Makoto Ando Spirodiamine-diaryl ketoxime derivative
ES2624828T3 (es) 2008-07-16 2017-07-17 Synergy Pharmaceuticals Inc. Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros
JPWO2010013595A1 (ja) 2008-07-30 2012-01-12 Ｍｓｄ株式会社 ５員−５員又は５員−６員縮環シクロアルキルアミン誘導体
WO2010047982A1 (fr) 2008-10-22 2010-04-29 Merck Sharp & Dohme Corp. Nouveaux dérivés de benzimidazole cycliques utiles comme agents anti-diabétiques
CA2741672A1 (fr) 2008-10-31 2010-05-06 Merck Sharp & Dohme Corp. Nouveaux agents antidiabetiques utiles avec des derives de benzimidazole cycliques
WO2011051327A2 (fr) 2009-10-30 2011-05-05 Novartis Ag Petites protéines à chaîne unique de type anticorps
WO2011051466A1 (fr) 2009-11-02 2011-05-05 Novartis Ag Molécules de liaison anti-idiotypiques à base de fibronectine et leurs utilisations
WO2011092233A1 (fr) 2010-01-29 2011-08-04 Novartis Ag Conjugaison de levures pour produire des combinaisons de liants à base de fibronectine à haute affinité
AU2011218830B2 (en) 2010-02-25 2014-07-24 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
CA2798432A1 (fr) 2010-05-06 2011-11-10 Novartis Ag Compositions et procedes d'utilisation d'anticorps therapeutiques diriges contre la proteine 6 liee a la lipoproteine de basse densite (lrp6)
SI2606070T1 (sl) 2010-08-20 2017-04-26 Novartis Ag Protitelesa za receptor 3 epidermalnega rastnega faktorja (HER3)
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
EP2643353A1 (fr) 2010-11-24 2013-10-02 Novartis AG Molécules multi-spécifiques
EP3243385B1 (fr) 2011-02-25 2021-01-13 Merck Sharp & Dohme Corp. Nouveaux dérivés d'azabenzimidazole cyclique utiles en tant qu'agents antidiabétiques
MX2014005411A (es) 2011-11-04 2015-02-12 Novartis Ag Construcciones prolongadas de la vida media de la proteina relacionada con lipoproteina de baja densidad 6 (lrp6).
WO2013084148A2 (fr) 2011-12-05 2013-06-13 Novartis Ag Anticorps pour le récepteur 3 du facteur de croissance épidermique (her3) dirigé contre le domaine ii de her3
ES2758433T3 (es) 2011-12-05 2020-05-05 Novartis Ag Anticuerpos contra el receptor 3 del factor de crecimiento epidérmico (HER3)
JP2015525782A (ja) 2012-08-02 2015-09-07 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． 抗糖尿病性三環式化合物
CN104994848A (zh) 2013-02-22 2015-10-21 默沙东公司 抗糖尿病二环化合物
CN105246916A (zh) 2013-03-14 2016-01-13 诺华股份有限公司 针对notch 3的抗体
WO2014139388A1 (fr) 2013-03-14 2014-09-18 Merck Sharp & Dohme Corp. Nouveaux dérivés d'indole utiles en tant qu'agents antidiabétiques
CA2905435A1 (fr) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Compositions utiles pour le traitement de troubles gastro-intestinaux
CA2905438A1 (fr) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Agonistes de la guanylate cyclase et leurs utilisations
PT3004138T (pt) 2013-06-05 2024-06-18 Bausch Health Ireland Ltd Agonistas ultrapuros de guanilato ciclase c, método de produção e utilização dos mesmos
WO2015051496A1 (fr) 2013-10-08 2015-04-16 Merck Sharp & Dohme Corp. Composés tricycliques antidiabétiques
WO2015163488A1 (fr) 2014-04-25 2015-10-29 Ajinomoto Co., Inc. Agent immunostimulant
WO2017073797A1 (fr) 2015-10-28 2017-05-04 Ajinomoto Co., Inc. Agent immunostimulant
US20210198368A1 (en) 2016-01-21 2021-07-01 Novartis Ag Multispecific molecules targeting cll-1
CN110590855B (zh) 2016-01-25 2023-05-12 沈阳药科大学 铂类配合物的制备方法及其含有该铂类配合物的脂质体与制备方法
US11072602B2 (en) 2016-12-06 2021-07-27 Merck Sharp & Dohme Corp. Antidiabetic heterocyclic compounds
WO2018132876A1 (fr) * 2017-01-19 2018-07-26 The University Of Sydney Nouveaux inhibiteurs de transport de glycine pour le traitement de la douleur
CA3064068A1 (fr) * 2017-05-22 2018-11-29 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Amides d'acides gras et leurs utilisations dans le traitement de troubles de la dependance et d'etats lies a la dependance
EP3802611A2 (fr) 2018-06-01 2021-04-14 Novartis AG Molécules de liaison dirigées contre bcma et leurs utilisations
WO2020109978A1 (fr) 2018-11-26 2020-06-04 Novartis Ag Polypeptides de fusion de lpl-gpihbp1
UY38701A (es) 2019-05-21 2020-12-31 Novartis Ag Moléculas de unión a cd19, conjugados, composiciones que las comprenden y usos de las mismas
WO2020236797A1 (fr) 2019-05-21 2020-11-26 Novartis Ag Domaines de cd58 variants et leurs utilisations
CA3199095A1 (fr) 2020-11-06 2022-05-12 Novartis Ag Molecules de liaison a cd19 et utilisations associees
WO2023209568A1 (fr) 2022-04-26 2023-11-02 Novartis Ag Anticorps multispécifiques ciblant il-13 et il-18
WO2024130158A1 (fr) 2022-12-16 2024-06-20 Modernatx, Inc. Nanoparticules lipidiques et polynucléotides codant l'interleukine-22 à demi-vie sérique étendue pour le traitement d'une maladie métabolique

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1271623B (it) * 1994-03-21 1997-06-04 Lifegroup Spa N-acilderivati di aminoalcoli con acidi monocarbossilici e bicarbossilici con attivita' neuroprotettiva nelle patologie neurologiche correlate ad eccitotossicita'
IT1271267B (it) * 1994-12-14 1997-05-27 Valle Francesco Della Ammidi di acidi mono e bicarbossilici con amminoalcoli,selettivamente attive sul recettore periferico dei cannabinoidi
IT1271266B (it) * 1994-12-14 1997-05-27 Valle Francesco Della Impiego terapeutico di ammidi di acidi mono e bicarbossilici con amminoalcoli,selettivamente attive sul recettore periferico dei cannabinoidi

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO03006007A1 *

Also Published As

Publication number Publication date
WO2003006007A1 (fr) 2003-01-23
ITMI20011483A0 (it) 2001-07-11
ITMI20011483A1 (it) 2003-01-11

Similar Documents

Publication Publication Date Title
EP1425004A1 (fr) Utilisation de composes en tant qu'antagonistes fonctionnels des recepteurs cannabinoides centraux
JP4216330B2 (ja) 末梢カンナビノイドレセプターで作用する薬物製造でのモノおよびビカルボン酸アミドの利用
JP4111349B2 (ja) カンナビノイド末梢レセプターに選択的に作用するモノおよびビカルボン酸のアミノ酸あるいはグリコサミンとのアミド類
KR20080047956A (ko) 발기부전의 치료 및 예방을 위한 약제 조성물
JP2010512413A (ja) アンフェタミンの非標準アミノ酸結合体およびそれらの製造方法および使用方法
JPH08512048A (ja) 例えばｎ−（３−オキシヘキサノイル）ホモセリンラクトンのような免疫抑制剤及び抗アレルギー性化合物
CA2722491C (fr) Formulation pharmaceutique contenant de l'ethanolamide palmitoyle et de l'ethanolamide stearoyle
JP2002506440A (ja) プロスタグランジン製薬組成物
EP1592418B1 (fr) Composes de type endocannabinoide pour traiter pathologies dégénératives du cns
WO2016014242A1 (fr) Compositions comprenant des dérivés bioréversibles d'hydroxy-2-aminotétralines n-substituées, formes posologiques et procédés associés
AU737454B2 (en) Method for inhibiting the growth of mammalian cells
EP3302451A1 (fr) Combinaison comprenant du palmitoyléthanolamide (pea) et du e lycopène pour utilisation dans le traitement de maladies inflammatoires
EP4370109A1 (fr) Médicaments à base d'acide subéroylanilide hydroxamique (saha), conjugués et nanoparticules, et leurs procédés d'utilisation
EP0393180A1 (fr) 26-aminocholesterol ainsi que derives et analogues de ce compose utilises dans la regulation de l'accumulation de cholesterol dans les tissus corporels.
CN116133693A (zh) 载药的大分子及其制备方法
JPH09510467A (ja) 興奮毒性に関連した神経病理学的な状態において神経保護作用を行う薬剤の製造におけるアミノアルコールのｎ−アシル誘導体の使用
CN114621242A (zh) 加兰他敏的衍生物及制剂
TW541295B (en) A novel substituted alkylteraamine derivative for use as tachykinin antagonist
WO2023086564A1 (fr) Composé imidazo[4,5-b]pyridine cristallin, compositions pharmaceutiques et leur utilisation dans le traitement d'états médicaux
WO2024015447A1 (fr) Préparation de sels, d'esters et de conjugués de psilocine stables et leurs utilisations
LV15575B (lv) Selenofēnhromēnu deiterēti analogi, to iegūšana un izmantošana
JPH0881365A (ja) 酸化ストレス抑制剤

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20040211

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LI LU MC NL PT SE SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO SI

RIN1 Information on inventor provided before grant (corrected)

Inventor name: DALLE CARBONARE, MAURIZIO

Inventor name: LEON, ALBERTA

17Q First examination report despatched

Effective date: 20080229

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: RESEARCH & INNOVATION S.P.A.

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20110712